Aeglea BioTherapeutics Stock News

Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of

WALTHAM, Mass. , Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to trans

WALTHAM, Mass. , Nov. 3, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to trans

NEW YORK , Nov. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) on behalf of the company's shareholders.  The investigat

WALTHAM, Mass. , Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to trans

WALTHAM, Mass. , Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transf

WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to tra

WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to trans

Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, i

On July 19, 2023, Polar Capital Holdings Plc (Trades, Portfolio), a London-based investment firm, made a significant move in the biotechnology sector by investing in 3,936,198 shares in Aeglea BioTher

Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing

Are you looking for the best penny stocks to watch right now? With all of the excitement in the stock market today, you're not alone.

With the uptick of volatility in the stock market today, there's no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or ra

The Fourth of July Holiday in 2023 will see the stock market closed for a full session. But that doesn't mean fewer opportunities to make money in the stock market.

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.